Saturday 17 October 2026
Export UPC’s income statement to Excel — free account
Universe Pharmaceuticals INC
UPC Healthcare Drug Manufacturers Specialty & Generic
Universe Pharmaceuticals INC’s revenue for fiscal 2025 (year ended September 2025) was $17.9 million, down 22.4% from fiscal 2024.
3.97
0.18
−4.34%
Follow UPC
| Older periods | Sep '24 | Mar '25 | Sep '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.37 | 2.60 | 3.71 | 3.75 | |
Current Ratio |
2.54 | 2.78 | 4.07 | 4.05 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
11.76% | 9.58% | 13.36% | 13.37% | |
Debt/Equity |
0.18 | 0.14 | 0.16 | 0.17 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.50) | (0.49) | (0.50) | (1.39) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(9.75) | 2.43 | (5.31) | (4.62) | |
Working Capital |
31.33 | 41.61 | 40.43 | 41.56 | |
Capital Expenditures |
(0.24) | (0.13) | (0.26) | (0.32) | |
Net Current Asset Value |
29.19 | 39.54 | 40.43 | 39.39 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
16.88 | 15.52 | 14.14 | 18.26 | |
Average Payables |
4.00 | 9.32 | 3.13 | 5.76 | |
Average Inventory |
1.97 | 3.22 | 2.77 | 2.68 | |
Average Assets |
63.75 | 75.52 | 55.51 | 60.45 | |
Average Common Equity |
45.97 | 51.16 | 42.03 | 41.19 |
Columns are period end dates